Neurocrine Biosciences: NBI-921352
TCSF is thrilled to announce that Neurocrine Biosciences' SCN8A study is now up on clinicaltrials.gov.
This is a study to evaluate NBI-921352 as adjunctive therapy in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) in patients age 12-21*. This is the first SCN8A specific clinical trial and is a huge step forward for our community! Click the link above to learn more about inclusion and exclusion criteria.
*As of January 2022, the FDA accepted Neurocrine's protocol amendment that expands the study population to include subjects aged between 2 and 11 years as well.
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center
877-641-3461
medinfo@neurocrine.com
ClinicalTrials.gov identifier (NCT number): NCT04873869
*As of January 2022, the FDA accepted Neurocrine's protocol amendment that expands the study population to include subjects aged between 2 and 11 years as well.
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center
877-641-3461
medinfo@neurocrine.com
ClinicalTrials.gov identifier (NCT number): NCT04873869
Trial Sites
(USA only, More sites to come)
|
Recruiting
|
Not Yet Recruiting
|
|
|
The Cute Syndrome is registered as a tax-exempt organization under IRS section 501(c)(3).
Our tax identification number is: 46-2699066. © The Cute Syndrome Foundation, All rights reserved
|
